Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Role of Biomarkers for the Diagnosis of Prion Diseases

Version 1 : Received: 19 February 2022 / Approved: 24 February 2022 / Online: 24 February 2022 (10:00:00 CET)

A peer-reviewed article of this Preprint also exists.

Altuna, M.; Ruiz, I.; Zelaya, M.V.; Mendioroz, M. Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review. Medicina 2022, 58, 473. Altuna, M.; Ruiz, I.; Zelaya, M.V.; Mendioroz, M. Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review. Medicina 2022, 58, 473.

Abstract

Prion diseases are progressive and irreversible neurodegenerative disorders with a low incidence (1.5–2 cases per million per year). Genetic (10-15%), acquired (anecdotal) and sporadic (85%) forms of the disease have been described. The clinical spectrum of prion diseases is very varied, although the most common symptoms are rapidly progressive dementia, cerebellar ataxia and myoclonus. Mean life expectancy from the onset of symptoms is 6 months. There are currently diagnostic criteria based on clinical phenotype as well as neuroimaging biomarkers (magnetic resonance imaging), neurophysiological tests (electroencephalogram and polysomnogram) and cerebrospinal fluid biomarkers (14-3-3 protein and real-time quaking induced conversion (RT-QuIC)). The sensitivity and specificity of some of these tests (electroencephalogram and 14-3-3 protein) is under debate and the applicability of other tests such as RT-QuIC is not universal. However, the usefulness of these biomarkers beyond the most frequent prion disease, sporadic Creutzfeldt-Jakob disease, remains unclear. Therefore, research is being carried out on new, more efficient cerebrospinal fluid biomarkers (total tau, ratio total tau/phosphorylated tau and neurofilament light chain) and potential blood biomarkers (neurofilament light chain among others) to try to universalize access to early diagnosis in the case of prion diseases.

Keywords

prion disease; biomarkers; diagnosis; dementia; neurodegeneration

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.